Research.Patient.info
High-Risk Non-Muscle Invasive Bladder Cancer research hub
2 indexed studies · 1 currently recruiting
- not yet recruitingPHASE3
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
This study compares two ways to treat high-risk bladder cancer that hasn't spread: standard BCG therapy (a medicine put into the bladder) versus a combination of radiotherapy and a special drug to make it work better. It aims to find a more effective and reliable treatment.
United Kingdom - active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
This study is looking into a new treatment for a type of bladder cancer called high-risk non-muscle invasive bladder cancer. It combines a drug called pembrolizumab with an existing treatment, BCG, to see if it works better and is safe.
United States · Australia · Austria